☆ 4.3 Letter

Protein kinase C expression is deregulated in chronic lymphocytic leukemia

LEUKEMIA & LYMPHOMA (2013)

Journal

LEUKEMIA & LYMPHOMA

Volume 54, Issue 10, Pages 2288-2290

Publisher

TAYLOR & FRANCIS LTD

DOI: 10.3109/10428194.2013.769220

Keywords

-

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Hematology

Exploring the pathways to chronic lymphocytic leukemia

Freda K. Stevenson, Francesco Forconi, Thomas J. Kipps

Summary: Research into chronic lymphocytic leukemia has led to significant improvements in the assessment and treatment of patients, with designer drugs now successfully targeting tumor cells based on their biology. Classifying CLL into unmutated (U) and mutated (M) diseases based on the mutational status of IGHV sequences reveals distinct origins, biology, and clinical behaviors for each. Despite advances, challenges such as cell-escape strategies and immunosuppression remain, necessitating continued research into CLL biology.

BLOOD (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Nucleosome repositioning in chronic lymphocytic leukemia

Kristan V. Piroeva, Charlotte Mcdonald, Charalampos Xanthopoulos, Chelsea Fox, Christopher T. Clarkson, Jan-Philipp Mallm, Yevhen Vainshtein, Luminita Ruje, Lara C. Klett, Stephan Stilgenbauer, Daniel Mertens, Efterpi Kostareli, Karsten Rippe, Vladimir B. Teif

Summary: This study compared the nucleosome positions in chronic lymphocytic leukemia (CLL) patients and healthy individuals, and found significant changes in nucleosome positioning in CLL. The spacing between nucleosomes was shortened, and changes in nucleosome occupancy were linked to chromatin remodeling and reduced DNA methylation. Nucleosome positioning can be used to classify CLL subtypes and monitor disease progression.

GENOME RESEARCH (2023)

Add to Collection

Article Hematology

Notch signaling promotes disease initiation and progression in murine chronic lymphocytic leukemia

Delphine Tardivon, Mateusz Antoszewski, Nadine Zangger, Marianne Nkosi, Jessica Sordet-Dessimoz, Rudi Hendriks, Ute Koch, Freddy Radtke

Summary: NOTCH1 gain-of-function mutations are common in B-cell chronic lymphocytic leukemia, and play a role in disease progression and chemotherapy resistance. In an in vivo mouse model of CLL, activation of Notch signaling facilitated disease initiation and promoted CLL cell proliferation and disease progression, while inhibition of Notch signaling delayed disease induction.

BLOOD (2021)

Add to Collection

Article Oncology

mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia

Natasha Malik, Jodie Hay, Hassan N. B. Almuhanna, Karen M. Dunn, Jamie Lees, Jennifer Cassels, Jiatian Li, Rinako Nakagawa, Owen J. Sansom, Alison M. Michie

Summary: This study reveals the essential role of mTORC1 in the initiation/maintenance of leukemia in a CLL model and identifies the inactivation of eEF2 activity as a novel therapeutic target for blocking CLL progression.

LEUKEMIA (2023)

Add to Collection

Article Hematology

FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia

Vaclav Seda, Eva Vojackova, Laura Ondrisova, Lenka Kostalova, Sonali Sharma, Tomas Loja, Gabriela Mladonicka Pavlasova, Daniel Zicha, Marie Kudlickova Peskova, Jan Krivanek, Kvetoslava Liskova, Leos Kren, Vladimir Benes, Katerina Musilova Litzmanova, Marek Borsky, Jan Oppelt, Jan Verner, Sarka Pospisilova, Yvona Brychtova, Anna Panovska, Zhi Tan, Shuxing Zhang, Michael Doubek, Katerina Amruz Cerna, Jiri Mayer, Marek Mraz

Summary: The migration and survival of CLL cells are influenced by GAB1, which can be targeted for therapeutic purposes, especially in combination with BTK inhibitors.

BLOOD (2021)

Add to Collection

Article Hematology

The protein landscape of chronic lymphocytic leukemia

Fabienne Meier-Abt, Junyan Lu, Ester Cannizzaro, Marcel F. Pohly, Sandra Kummer, Sibylle Pfammatter, Laura Kunz, Ben C. Collins, Ferran Nadeu, Kwang Seok Lee, Peng Xue, Myriam Gwerder, Michael Roiss, Jennifer Huellein, Sebastian Scheinost, Sascha Dietrich, Elias Campo, Wolfgang Huber, Ruedi Aebersold, Thorsten Zenz

Summary: This study uncovered mutations affecting protein expression in CLL and identified signaling pathways associated with trisomy 12. STAT2 protein expression was linked to specific drug responses, providing a protein expression reference map for CLL.

BLOOD (2021)

Add to Collection

Review Oncology

Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia

Andrew H. Lipsky, Nicole Lamanna

Summary: Targeted therapies have revolutionized the frontline treatment for CLL, reducing reliance on chemoimmunotherapy. Drugs such as ibrutinib, acalabrutinib, and venetoclax have shown efficacy in oral therapy. This review explores novel therapeutic strategies using these agents in combination, highlighting the importance of patient characteristics and study methodology.

CANCER (2023)

Add to Collection

Article Hematology

RPS15 mutations rewire RNA translation in chronic lymphocytic leukemia

Stavroula Ntoufa, Marina Gerousi, Stamatia Laidou, Fotis Psomopoulos, Georgios Tsiolas, Theodoros Moysiadis, Nikos Papakonstantinou, Larry Mansouri, Achilles Anagnostopoulos, Niki Stavrogianni, Sarka Pospisilova, Karla Plevova, Antonios M. Makris, Richard Rosenquist, Kostas Stamatopoulos

Summary: Recurrent mutations in the RPS15 gene have been found to rewire the translation program of primary CLL cells, reducing their translational efficiency, with effects not observed in cell lines. Specifically, RPS15 mutations alter the translation efficiency of other ribosomal proteins and regulatory elements, impacting key cellular processes and immune signaling.

BLOOD ADVANCES (2021)

Add to Collection

Article Oncology

The PKN1-TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia

Maria Edilova, Jaclyn C. Law, Safoura Zangiabadi, Kenneth Ting, Achire N. Mbanwi, Andrea Arruda, David Uehling, Methvin Isaac, Michael Prakesch, Rima Al-awar, Mark D. Minden, Ali A. Abdul-Sater, Tania H. Watts

Summary: The study shows that PKN1 plays a crucial role in CLL by protecting TRAF1, and inhibitors like OTSSP167 and XL-228 can induce CLL cell death by reducing TRAF1. These findings suggest the PKN1-TRAF1 signaling axis as a potential new target for CLL.

ONCOIMMUNOLOGY (2021)

Add to Collection

Article Hematology

Chronic lymphocytic leukemia: disease biology

Stefan Koehrer, Jan A. Burger

Summary: B cell receptor signaling plays a crucial role in chronic lymphocytic leukemia (CLL). Targeting BCR-related kinases, such as Bruton tyrosine kinase (BTK), has shown high therapeutic efficacy by blocking CLL cell proliferation and inducing remissions. These kinase inhibitors also disrupt tissue homing receptor signaling, mobilizing CLL cells from lymphatic tissues into the peripheral blood.

ACTA HAEMATOLOGICA (2023)

Add to Collection

Article Oncology

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia

Xue Yi, Nitin Jain, LaKesla R. Iles, Mary L. Ayres, William G. Wierda, Varsha Gandhi

Summary: The B-cell receptor signaling pathway and Bcl-2 family prosurvival proteins play important roles in chronic lymphocytic leukemia. Combined treatment with ibrutinib and venetoclax shows high rates of remission in CLL patients, but some patients do not achieve complete remission. This study suggests that cells persistent during ibrutinib and venetoclax therapy might be sensitive to the combined use of venetoclax and Mcl-1 inhibitor AMG-176.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Hematology

TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target

Emma Kennedy, Eve Coulter, Emma Halliwell, Nuria Profitos-Peleja, Elisabeth Walsby, Barnaby Clark, Elizabeth H. Phillips, Thomas A. Burley, Simon Mitchell, Stephen Devereux, Christopher D. Fegan, Christopher Jones, Rosalynd Johnston, Tim Chevassut, Ralph Schulz, Martina Seiffert, Angelo Agathanggelou, Ceri Oldreive, Nicholas Davies, Tatjana Stankovic, Triantafillos Liloglou, Chris Pepper, Andrea G. S. Pepper

Summary: Despite the advancements in B-cell receptor-targeted inhibitors, CLL remains incurable. TLR9 activation by unmethylated DNA is associated with disease progression in CLL. High TLR9 expression promotes CLL cell migration and disease progression, while dual targeting of TLR9 and BTK shows strong synergism as a potential treatment strategy for this incurable disease.

BLOOD (2021)

Add to Collection

Review Hematology

Overcoming resistance to targeted therapies in chronic lymphocytic leukemia

Sigrid S. Skanland, Anthony R. Mato

Summary: Insight into the mechanisms of resistance to targeted therapies in chronic lymphocytic leukemia (CLL) has led to the development of strategies to prevent and overcome resistance, including combination therapies targeting bypass mechanisms, temporally sequencing of therapies, improved clinical trial designs, and real-time monitoring of patient response. These approaches aim to secure effective treatment options at the relapsed setting and overcome acquired resistance to existing therapies.

BLOOD ADVANCES (2021)

Add to Collection

Article Cell Biology

Naturally Occurring Bicoumarin Compound Daphnoretin Inhibits Growth and Induces Megakaryocytic Differentiation in Human Chronic Myeloid Leukemia Cells

Yu-Chuen Huang, Chun-Ping Huang, Chin-Ping Lin, Kai-Chien Yang, Yu-Jie Lei, Hao-Pei Wang, Yueh-Hsiung Kuo, Yu-Jen Chen

Summary: Daphnoretin extracted from the stem and roots of Wikstroemia indica has been found to inhibit cell growth and induce megakaryocytic differentiation in chronic myeloid leukemia cells. It shows potential as a differentiation therapy agent for CML, but further investigations are needed to validate its efficacy in vivo and in patients.

CELLS (2022)

Add to Collection

Article Oncology

A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia

Deepti Gadi, Alec Griffith, Svitlana Tyekucheva, Zixu Wang, Vanessa Rai, Alexander Vartanov, Emily Thrash, Stacey M. Fernandes, Timothy Z. Lehmberg, Brandon Lee, Stephen P. Martindale, John-Hanson Machado, Oreofe Odejide, Philippe Armand, David C. Fisher, Jon Arnason, Matthew S. Davids, James A. Lederer, Jennifer R. Brown

Summary: Combination therapy with the PI3K delta gamma inhibitor duvelisib and chemoimmunotherapy shows promising efficacy in treating CLL patients, but approximately one-third of patients develop autoimmune toxicity. The treatment modulates CD4 and CD8 T cell subsets as well as pro-inflammatory cytokines, resulting in an increase in activated CD8 T cells and Th17 T cells.

LEUKEMIA (2022)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

Mechanisms of Anticancer Therapy Resistance: The Role of Cancer Stem Cells

Julhash U. Kazi

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Article Oncology

The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia

Kinjal Shah, Mehreen Ahmed, Julhash U. Kazi

Summary: Glucocorticoids are commonly used in cancer treatment, and this study found that sensitivity to dexamethasone is correlated with gene expression patterns in patients with acute lymphoblastic leukemia. Resistance to dexamethasone may involve key signaling proteins such as Aurora kinase, S6K, and others.

NPJ PRECISION ONCOLOGY (2021)

Add to Collection

Meeting Abstract Hematology

Treatment Shapes Clonal Evolution and Resistance Patterns in Murine KMT2A-Rearranged Leukemia with Subclonal FLT3 N676K

Ton Falques, Mattias Pilheden, Qirui Zhang, Louise Ahlgren, Helena Sturesson, Lars Ronnstrand, Axel Hyrenius Wittsten, Julhash U. Kazi, Anna Hagstroem-Andersson

BLOOD (2021)

Add to Collection

Review Oncology

Phosphorylation-Dependent Regulation of WNT/Beta-Catenin Signaling

Kinjal Shah, Julhash U. Kazi

Summary: WNT/beta-catenin signaling pathway is highly complex and plays diverse roles in cellular processes, dependent on the type of co-receptors used for signaling in β-catenin-dependent or -independent manner. These pathways involve cross-talk with intertwined networks, different ligands, receptors, and co-receptors, directly phosphorylating β-catenin by various kinases, and determining pathway output in terms of gene induction through associated co-activators.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Cell Biology

Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance

Kristina B. Emdal, Nicolas Palacio-Escat, Caroline Wigerup, Akihiro Eguchi, Helen Nilsson, Dorte B. Bekker-Jensen, Lars Ronnstrand, Julhash U. Kazi, Alexandre Puissant, Raphael Itzykson, Julio Saez-Rodriguez, Kristina Masson, Peter Blume-Jensen, Jesper V. Olsen

Summary: In this study, the signaling responses of Selinexor in AML patients and cell lines were investigated using phosphoproteomics. The study identified key targetable signaling hubs for rational drug combinations by scoring the phosphorylation sites of P53. Furthermore, combining Selinexor with AKT inhibitor MK-2206 overcame dysregulated AKT-FOXO3 signaling in resistant cells, resulting in synergistic anti-proliferative effects.

CELL REPORTS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer

Ahmad Nasimian, Mehreen Ahmed, Ingrid Hedenfalk, Julhash U. Kazi

Summary: In this study, a gene signature was defined through the analysis of cisplatin-perturbed gene expression and pathway enrichment, and a cisplatin sensitivity prediction model was developed using the TabNet algorithm. The TabNet model outperformed other machine learning models with an accuracy of over 80%. Furthermore, BCL2L1 was identified as an important gene contributing to cisplatin resistance, and its pharmacological inhibition was found to enhance cisplatin efficacy. This study developed a tool to predict cisplatin sensitivity and identified BCL2L1 as a significant gene in this context.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2023)

Add to Collection

Article Biochemistry & Molecular Biology

A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia

Ahmad Nasimian, Lina Al Ashiri, Mehreen Ahmed, Hongzhi Duan, Xiaoyue Zhang, Lars Roennstrand, Julhash U. Kazi

Summary: Despite progress in cancer treatment, therapy resistance remains a major obstacle for long-term survival. By using highly variable genes and pharmacogenomic data, a drug sensitivity prediction model for the tyrosine kinase inhibitor sorafenib was developed with over 80% accuracy. AXL was identified as an important feature for drug resistance and PKC signaling was found to be enriched in drug-resistant patient samples. Inhibition of tyrosine kinase activity enhanced AXL expression and phosphorylation of the PKC-substrate CREB protein, showing synergy with AXL and PKC inhibitors.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling

Kinjal Shah, Lina Al Ashiri, Ahmad Nasimian, Mehreen Ahmed, Julhash U. Kazi

Summary: Therapy resistance in cancer treatment, specifically T-cell acute lymphoblastic leukemia (T-ALL), is linked to the deregulation of the anti-apoptotic protein BCL2 and is mediated through distinct gene signatures and cytokine signaling pathways. Different T-ALL cell lines display varying response to BCL2 inhibition, and prolonged exposure to venetoclax leads to the development of resistance. The expression of BCL2 family genes and global gene expression profiles, including cancer stem cell-related genes, differ between resistant cells and sensitive cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Biochemistry & Molecular Biology

DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors

Anbu Liu, Shaoting Zhang, Ming Wang, Liangying Zhang, Shidong Xu, Ahmad Nasimian, Shujing Li, Sien Zhao, Xu Cao, Jinhai Tian, Yuanyuan Yu, Zhaoyang Fan, Kun Xiao, Hui Zhao, Julhash U. Kazi, Lijun Ma, Jianmin Sun

Summary: This study demonstrates that DDR1/2 contribute to KIT activation and enhance resistance to imatinib in GISTs, providing a rationale for further exploration of DDR1/2 targeting in GIST treatment.

MOLECULAR CARCINOGENESIS (2023)

Add to Collection

Article Oncology

Understanding the Role of Activation Loop Mutants in Drug Efficacy for FLT3-ITD

Julhash U. Kazi, Lina Al Ashiri, Rituraj Purohit, Lars Ronnstrand

Summary: This study investigated the impact of FLT3 mutations on its function and interaction with therapeutic drugs in acute myeloid leukemia (AML). The findings provide insights for tailored treatments and highlight the significance of customized medical approaches in AML therapy.

CANCERS (2023)

Add to Collection

Meeting Abstract Oncology

Mechanism of AXL regulation in chemotherapy resistance

Mehreen Ahmed, Julhash Uddin Kazi

CANCER RESEARCH (2022)

Add to Collection

Review Biochemistry & Molecular Biology

T cell receptor (TCR) signaling in health and disease

Kinjal Shah, Amr Al-Haidari, Jianmin Sun, Julhash U. Kazi

Summary: Interaction of T cell receptor with MHC-antigenic peptide complex leads to activation of T cell signaling pathways that mediate gene expression. Adaptor proteins act as scaffolds in integrating these pathways to connect different signaling cascades, facilitating full T cell activation.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Machine learning in the prediction of cancer therapy

Raihan Rafique, S. M. Riazul Islam, Julhash U. Kazi

Summary: Resistance to cancer therapy is a major cause of treatment failure and death, with current treatment plans depending on cancer subtypes and genetic mutations. While predictive models using artificial intelligence show promise, challenges remain in building clinically usable models due to a lack of clinically relevant pharmacogenomic data.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2021)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.